OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder
MIAMI, March 22, 2017 (GLOBE NEWSWIRE) -- OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. (NASDAQ:OPK) announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products …